Arch Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended June 30, 2022
For the nine months, sales was USD 0.014086 million compared to USD 0.01 million a year ago. Net loss was USD 3.39 million compared to USD 4.48 million a year ago. Basic loss per share from continuing operations was USD 2 compared to USD 4 a year ago.